Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth

BMC Research Notes

Abraham Aseffa⁴  Asrat Hailu²  T Mark Doherty³  Peter Bang¹  Girmay Medhin⁵  Lawrence Yamuah⁴  Menberework Chanyalew⁴  Ahmed Bedru⁴  Adane Mihret²  Martha Zewdie⁴  Markos Abebe⁴  Jemal Hussein⁴  Alemnew F Dagnew⁶ 

[1] Statens Serum Institut, Copenhagen, Denmark;Department of Microbiology, Immunology and Parasitology, Faculty of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia;Current address: GSK, Brøndby, Denmark;Armauer Hansen Research Institute, Addis Ababa, Ethiopia;Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia;Current address: Global Development, Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena, 53100, Italy

关键词: Ethiopia;    Interferon-γ release assay;    Tuberculin skin test;    BCG;    Latent;    Tuberculosis;   

Others  :  1165986
DOI  :  10.1186/1756-0500-5-415

 received in 2012-05-16, accepted in 2012-08-01,  发布年份 2012

【 摘 要 】

Background

One third of the world’s population is thought to have latent tuberculosis infection (LTBI) with the potential for subsequent reactivation of disease. To better characterize this important population, studies comparing Tuberculin Skin Test (TST) and the new interferon-γ release assays including QuantiFERON®-TB Gold In-Tube (QFT-GIT) have been conducted in different parts of the world, but most of these have been in countries with a low incidence of tuberculosis (TB). The aim of this study was therefore to evaluate the use of QFT-GIT assay as compared with TST in the diagnosis of LTBI in Ethiopia, a country with a high burden of TB and routine BCG vaccination at birth.

Methods

Healthy medical and paramedical male students at the Faculty of Medicine, Addis Ababa University, Ethiopia were enrolled into the study from December 2008 to February 2009. The TST and QFTG-IT assay were performed using standard methods.

Results

The mean age of the study participants was 20.9 years. From a total of 107 study participants, 46.7% (95%CI: 37.0% to 56.6%) had a positive TST result (TST≥10 mm), 43.9% (95%CI: 34.3% to 53.9%) had a positive QFT-GIT assay result and 44.9% (95%CI: 35.2% to 54.8%) had BCG scar. There was strong agreement between TST (TST ≥10mm) and QFT-GIT assay (Kappa = 0.83, p value = 0.000).

Conclusion

The TST and QFT-GIT assay show similar efficacy for the diagnosis of LTBI in healthy young adults residing in Ethiopia, a country with high TB incidence.

【 授权许可】

   
2012 Dagnew et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Djelouadji Z, Raoult D, Daffe M, Drancourt M: A single-step sequencing method for the identification of Mycobacterium tuberculosis complex species. PLoS Negl Trop Dis 2008, 2:e253.
• [2]Ahmad S: Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol 2011, 2011:814943.
• [3]Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999, 282:677-686.
• [4]American Thoracic Society/Centers for Disease Control and Prevention: Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005, 172:1169-1227.
• [5]Public Health Agency of Canada and Canadian Lung Association: Canadian Tuberculosis Standards. Ottawa: PublicHealth Agency of Canada and Canadian Lung Association; 2011.
• [6]World Health Organization: Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO; 2011.
• [7]World Health Organization: TB/HIV Clinical Manual. Geneva: WHO; 2004.
• [8]Rowland R, McShane H: Tuberculosis vaccines in clinical trials. Expert Rev Vaccines 2011, 10:645-658.
• [9]Harboe M: Antigens of PPD, old tuberculin, and autoclaved Mycobacterium bovis BCG studied by crossed immunoelectrophoresis. Am Rev Respir Dis 1981, 124:80-87.
• [10]Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
• [11]Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger JP, Huitric E, Sandgren A, Manissero D: Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37:88-99.
• [12]Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM, VACSEL Study Group: Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006, 13:179-186.
• [13]American Thoracic Society/Centers for Disease Control and Prevention: Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000, 161:1376-1395.
• [14]QuantiFERON-TB Gold package insert. http://www.cellestis.com/irm/content/pdf/AUS_July%202011_package_insert.pdf webcite
• [15]Byrt T: How good is that agreement? Epidemiology 1996, 7:561.
• [16]Pai M, Dendukuri N, Wang L, Joshi R, Kalantri S, Rieder HL: Improving the estimation of tuberculosis infection prevalence using T-cell-based assay and mixture models. Int J Tuberc Lung Dis 2008, 12:895-902.
• [17]Legesse M, Ameni G, Mamo G, Medhin G, Bjune G, Abebe F: Community-based cross-sectional survey of latent tuberculosis infection in Afar pastoralists, Ethiopia, using QuantiFERON-TB Gold In-Tube and tuberculin skin test. BMC Infect Dis 2011, 11:89. BioMed Central Full Text
• [18]Menzies R, Vissandjee B, Amyot D: Factors associated with tuberculin reactivity among the foreign-born in Montreal. Am Rev Respir Dis 1992, 146:752-756.
• [19]Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F: Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005, 40:211-217.
• [20]Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK: Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996, 178:1274-1282.
• [21]Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P: Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004, 170:65-69.
• [22]Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, Suzuki K, Inoue Y, Tsuyuguchi K, Sasaki Y, Mazurek GH, Tsuyuguchi I: Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004, 170:59-64.
• [23]Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM: A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002, 57:804-809.
• [24]Farhat M, Greenaway C, Pai M, Menzies D: False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006, 10:1192-1204.
• [25]Ozdemir D, Annakkaya AN, Tarhan G, Sencan I, Cesur S, Balbay O, Guclu E: Comparison of the tuberculin skin test and the quantiferon test for latent Mycobacterium tuberculosis infections in health care workers in Turkey. Jpn J Infect Dis 2007, 60:102-105.
• [26]Pottumarthy S, Morris AJ, Harrison AC, Wells VC: Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test. J Clin Microbiol 1999, 37:3229-3232.
• [27]Lienhardt C, Fielding K, Sillah J, Tunkara A, Donkor S, Manneh K, Warndorff D, McAdam KP, Bennett S: Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med 2003, 168:448-455.
• [28]Roelsgaard E, Iversen E, Blocher C: Tuberculosis in tropical Africa. An epidemiological study. Bull World Health Organ 1964, 30:459-518.
• [29]Legesse M, Ameni G, Mamo G, Medhin G, Shawel D, Bjune G, Abebe F: Knowledge and perception of pulmonary tuberculosis in pastoral communities in the middle and Lower Awash Valley of Afar region. Ethiopia. BMC Public Health 2010, 10:187.
• [30]Anderson RH, Sy FS, Thompson S, Addy C: Cigarette smoking and tuberculin skin test conversion among incarcerated adults. Am J Prev Med 1997, 13:175-181.
• [31]Leung CC, Yew WW, Law WS, Tam CM, Leung M, Chung YW, Cheung KW, Chan KW, Fu F: Smoking and tuberculosis among silicotic patients. Eur Respir J 2007, 29:745-750.
• [32]Leung CC, Yam WC, Yew WW, Ho PL, Tam CM, Law WS, Wong MY, Leung M, Tsui D: Comparison of T-Spot.TB and tuberculin skin test among silicotic patients. Eur Respir J 2008, 31:266-272.